Clinical Trial: Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients

U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07896252) titled 'Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients' on Oct. 14.

Brief Summary: This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: COPD Chronic Obstructive Pulmonary Disease (COPD) Lung Disease Chronic Lung Diseases, Obstructive

Intervention: DRUG: AERO-001

Double-blind

DRUG: AERO-002

Double-blind

DRUG: AERO-007

Double-blind

Recruitment Status: NOT_YET...